Bristol-Myers Squibb’s cancer immunotherapy Opdivo should soon be available to patients in England with advanced head and neck cancer, after NICE relented and allowed interim funding from the ...

In another slide titled 'Can I say the N-Word?', a flow chart outlined who is allowed to use the term, beginning with options for how employees identify themselves: white, a person of color but ...

The Fund aims to achieve capital growth over the medium to long term (at least 3 to 5 years). The Fund invests at least 80% in other collective investment schemes and exchange traded funds in order to ...

Relugolix–estradiol–norethisterone (relugolix combination therapy [CT]; Ryeqo, Gedeon Richter) is indicated 'in adult women of reproductive age for symptomatic treatment of endometriosis in women with ...

To enhance its cardiac care services, Archbold Memorial now offers HeartFlow CT technology, a state-of-the-art, non-invasive tool that helps evaluate and manage CAD with greater accuracy.

NCCT of the head performed for standard‐of‐care indications was used during the patient's hospital stay for analysis. When >1 CT scan was performed in a single day, the first NCCT performed that day ...

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Scott Kellacher Formation: 4 - 3 - 2 - 1 Manager: Thomas O'Ware ...

Strasbourg 2, Nice 2. Youssouf Ndayishimiye (Nice) header from the centre of the box to the bottom right corner. Assisted by Jonathan Clauss with a cross following a corner. Attempt missed.

Abstract: X-ray computed tomography (CT) is widely used for medical diagnosis and treatment planning; however, concerns about ionizing radiation exposure drive efforts to optimize image quality at ...

The authors of this study retrospectively evaluated the diagnostic yield of CT Head and the value of follow-up imaging, particularly MRI, in the evaluation of dizzy and vertiginous ED patients.

NICE has rejected Bristol Myers Squibb’s immunotherapy Opdivo as a second-line treatment for head and neck cancer in first draft guidance, unconvinced by evidence unearthed during a three-year ...